Calliditas acquires rights to Budenofalk in the USA

12 August 2019

Swedish drugmaker Calliditas Therapeutics (STO: CALTX) has exclusively in-licensed Budenofalk (budesonide) from Germany’s Dr Falk Pharma.

The deal relates to all indications for the US market, apart from orphan indications outside of liver targets, and attracts an upfron payment of 1.5 million euros ($1.7 million), plus regulatory related payments, subject to market approval from the US regulator.

The agreement is worth a total of 40 million euros, including future sales milestones, and comes with “typical royalties,” said the Swedish firm, whose shares were up 1.44% at 56.50 Swedish kronor by late afternoon trading.

Calliditas will leverage Dr Falk’s clinical trial data and expertise in liver indications, such as autoimmune hepatitis (AIH) with a view towards accelerating approval and market access.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK